NFKB1 and myeloid sarcoma: PPAR activators and inhibitors of NF-κB are currently being evaluated as potential therapeutics for MS (Dasgupta et al, 2007; Dunn et al, 2010; Klotz et al, 2005) mainly because they reduce the inflammatory component of the disease.